PIPELINE
PIPELINE
Targeting What Others Won't, Advancing What Others Can't
Targeting What Others Won't, Advancing What Others Can't
VivaMed BioPharma’s pipeline includes over 50 active drug assets—ranging from new chemical entities to repurposed drugs—focused on areas of critical unmet need. We prioritize conditions with high clinical urgency, limited treatment options, and strong scientific rationale. Our AI-powered development model helps us identify promising opportunities earlier and accelerate them through the pipeline with less risk, lower cost, and faster timelines.
VivaMed BioPharma’s pipeline includes over 50 active drug assets—ranging from new chemical entities to repurposed drugs—focused on areas of critical unmet need. We prioritize conditions with high clinical urgency, limited treatment options, and strong scientific rationale. Our AI-powered development model helps us identify promising opportunities earlier and accelerate them through the pipeline with less risk, lower cost, and faster timelines.
THERAPEUTIC AREAS
THERAPEUTIC AREAS
Focused Where Impact Is Most Urgent
Focused Where Impact Is Most Urgent
We develop therapies across five high-priority categories—each chosen for its clinical relevance, unmet need, and potential for scalable innovation.
We develop therapies across five high-priority categories—each chosen for its clinical relevance, unmet need, and potential for scalable innovation.
DEVELOPMENT STRATEGY
DEVELOPMENT STRATEGY
A Smarter, Faster Pipeline Model
A Smarter, Faster Pipeline Model
Unlike traditional pipelines that rely on a single asset, our model diversifies risk by developing multiple compounds across therapeutic areas and stages. We accelerate development using AI to model toxicity, optimize dosage, and draft regulatory and IP filings. We also prioritize repurposed drugs and novel formulations—leveraging existing safety data to cut time and cost from development timelines.
Unlike traditional pipelines that rely on a single asset, our model diversifies risk by developing multiple compounds across therapeutic areas and stages. We accelerate development using AI to model toxicity, optimize dosage, and draft regulatory and IP filings. We also prioritize repurposed drugs and novel formulations—leveraging existing safety data to cut time and cost from development timelines.
50+ active drug assets in development
150+ licensed or developed to date
39 regulatory approvals supported
AI-assisted development, from ideation to IND
Pipeline includes both breakthrough therapies and best-in-class repurposed drugs
